Investigational drug · Phase 2
HeXell-2020
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Coronary Artery Disease.
Phase 2Last checked: Nov 19, 2026Latest source record: Sep 29, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "HeXell-2020"
First trial start
2026
Aug 27, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "HeXell-2020", any sponsor or status.
Conditions studied
As listed on its trial records.
- Coronary Artery Disease
Approved drugs for the same conditions: Coronary artery disease and heart attack
Largest trials
Live from ClinicalTrials.gov: studies naming "HeXell-2020" as an intervention, largest first.
Hexun Biosciences Co., LTD.Industry
NCT07137104 · 39 participants (planned) · Start Aug 27, 2026 · Primary completion Dec 31, 2028
Drug: HeXell-2020 · For: Coronary Artery Disease
Sites: New Taipei City, Taiwan
- Safety and Tolerability Study of Mesenchymal Stem Cells, HeXell-2020, in Elderly Subjects With Mild to Moderate Frailty SyndromeNot yet recruiting
Hexun Biosciences Co., LTD.Industry
NCT07144072 · 12 participants (planned) · Start Dec 31, 2026 · Primary completion Dec 31, 2028
Drug: HeXell-2020 · For: Frailty in Older Adults
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Coronary Artery Disease
- ObicetrapibPhase 37 trials
NewAmsterdam Pharma · Lipidemia, Preclinical Alzheimer's Disease, Antioxidant Absorption
- ZiltivekimabPhase 34 trials
Novo Nordisk · Acute Myocardial Infarction (AMI), Myocardial Infarction, Heart Failure
- ezetimibe FDCPhase 32 trials
NewAmsterdam Pharma · Lipidemia, Coronary Artery Disease, Plaque, Atherosclerotic
- YN001Phase 22 trials
Beijing Inno Medicine Co., Ltd. · Atherosclerosis, Coronary Artery Disease, Atherosclerotic Cardiovascular Disease
- YMI024Phase 21 trial
Novartis · Coronary Artery Disease
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.